D. E. Shaw & Co., Inc. Cardiff Oncology, Inc. Transaction History

D. E. Shaw & Co., Inc.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$1.17 - $2.61 $30,193 - $67,353	-25,806 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$2.11 - $7.25 $54,450 - $187,093	25,806 New	25,806 $64,000
Q1 2021 May 17, 2021	SELL	$9.1 - $19.57 $111,693 - $240,202	-12,274 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$12.02 - $24.71 $147,533 - $303,290	12,274 New	12,274 $221,000

12.3M

813K

91.1K

Ticker CRDF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,334,900
Market Cap $184M
Description
Cardiff Oncology, Inc., a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; meta...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.